3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Neoplasms
3
Colorectal Neoplasms
3
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Histiocytosis, Langerhans-Cell
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Erdheim-Chester Disease
1
Ameloblastoma
1
Interventions
Paclitaxel
9
Carboplatin
8
Bevacizumab
8
fluzoparib
5
olaparib
3
Topotecan
3
Gemcitabine
3
liposomal doxorubicin
2
famitinib
2
apatinib
2
Oxaliplatin
2
Magnetic Resonance Spectroscopy
2
Indocyanine Green
2
Drug Therapy
2
Cisplatin
2
trametinib
1
senaparib
1
pembrolizumab
1
niraparib
1
montelukast
1
irinotecan sucrosofate
1
fludarabine
1
durvalumab
1
dalpiciclib
1
dabrafenib
1
ceralasertib
1
anlotinib
1
aldesleukin
1
Ultrasonography, Doppler
1
Therapeutics
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Ovarian Neoplasms
×
trametinib
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled